Raymond James Upgrades Oncolytics Biotech (TSE:ONC) to Moderate Buy

Oncolytics Biotech (TSE:ONC) was upgraded by stock analysts at Raymond James to a “moderate buy” rating in a research note issued to investors on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Trading Down 2.1 %

Shares of TSE:ONC traded down C$0.03 during mid-day trading on Thursday, hitting C$1.38. The stock had a trading volume of 95,200 shares, compared to its average volume of 71,027. The company’s 50 day moving average is C$1.50 and its 200-day moving average is C$1.45. Oncolytics Biotech has a 12-month low of C$1.15 and a 12-month high of C$2.32. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a market cap of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.